See more : Optomed Oyj (OPTOMED.HE) Income Statement Analysis – Financial Results
Complete financial analysis of Geron Corporation (GERN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Geron Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Learning Technologies Group plc (LTTHF) Income Statement Analysis – Financial Results
- Mineral & Financial Investments Limited (MAFL.L) Income Statement Analysis – Financial Results
- Hindustan Zinc Limited (HINDZINC.BO) Income Statement Analysis – Financial Results
- Newrange Gold Corp. (NRG.V) Income Statement Analysis – Financial Results
- Arcimoto, Inc. (FUV) Income Statement Analysis – Financial Results
Geron Corporation (GERN)
About Geron Corporation
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 237.00K | 596.00K | 1.39M | 253.00K | 460.00K | 1.07M | 1.07M | 6.16M | 36.37M | 1.15M | 1.28M | 2.71M | 2.44M | 3.56M | 1.73M | 2.80M | 7.62M | 3.28M | 290.00K | 1.05M | 1.17M | 1.25M | 3.62M | 6.61M | 5.40M | 6.80M | 7.30M | 5.30M |
| Cost of Revenue | 123.74M | 868.00K | 783.00K | 50.05M | 51.27M | 12.72M | 8.44M | 14.70M | 9.57M | 8.90M | 9.13M | 25.18M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4.65M | -3.70M | -1.70M | -1.60M | -1.20M |
| Gross Profit | -123.50M | -272.00K | 610.00K | -49.80M | -50.81M | -11.66M | -7.37M | -8.53M | 26.80M | -7.75M | -7.85M | -22.47M | 2.44M | 3.56M | 1.73M | 2.80M | 7.62M | 3.28M | 290.00K | 1.05M | 1.17M | 1.25M | 3.62M | 11.26M | 9.10M | 8.50M | 8.90M | 6.50M |
| Gross Profit Ratio | -52,110.97% | -45.64% | 43.79% | -19,683.40% | -11,046.09% | -1,093.53% | -692.21% | -138.48% | 73.68% | -671.99% | -611.93% | -829.42% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 170.40% | 168.52% | 125.00% | 121.92% | 122.64% |
| Research & Development | 125.05M | 95.52M | 85.73M | 51.49M | 52.07M | 13.43M | 11.03M | 18.05M | 17.83M | 20.71M | 23.16M | 51.37M | 69.32M | 61.69M | 57.62M | 53.66M | 54.62M | 41.23M | 35.08M | 30.08M | 25.55M | 31.57M | 29.02M | 23.55M | 20.60M | 15.60M | 15.10M | 14.30M |
| General & Administrative | 69.14M | 43.63M | 29.67M | 25.68M | 20.89M | 18.71M | 19.29M | 18.76M | 17.79M | 16.76M | 15.62M | 20.40M | 23.79M | 18.04M | 14.34M | 16.18M | 15.84M | 9.40M | 8.79M | 7.10M | 5.80M | 5.38M | 9.62M | 9.27M | 5.60M | 3.80M | 3.10M | 3.20M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 69.14M | 43.63M | 29.67M | 25.68M | 20.89M | 18.71M | 19.29M | 18.76M | 17.79M | 16.76M | 15.62M | 20.40M | 23.79M | 18.04M | 14.34M | 16.18M | 15.84M | 9.40M | 8.79M | 7.10M | 5.80M | 5.38M | 9.62M | 9.27M | 5.60M | 3.80M | 3.10M | 3.20M |
| Other Expenses | 0.00 | 1.00M | 1.10M | 168.00K | -69.00K | -154.00K | 0.00 | 0.00 | 1.31M | 0.00 | 0.00 | 5.45M | 5.45M | 35.00M | 57.62M | 0.00 | 54.62M | 0.00 | -5.87M | 45.15M | 0.00 | 0.00 | 0.00 | 4.65M | 3.70M | 1.70M | 1.60M | 1.20M |
| Operating Expenses | 194.18M | 139.15M | 115.39M | 77.17M | 72.97M | 32.14M | 30.32M | 36.81M | 35.62M | 37.47M | 38.78M | 71.77M | 93.11M | 79.73M | 71.96M | 69.85M | 70.46M | 50.64M | 38.00M | 37.19M | 31.35M | 36.95M | 38.64M | 37.47M | 29.90M | 21.10M | 19.80M | 18.70M |
| Cost & Expenses | 194.18M | 139.15M | 115.39M | 77.17M | 72.97M | 32.14M | 30.32M | 36.81M | 35.62M | 37.47M | 38.78M | 71.77M | 93.11M | 79.73M | 71.96M | 69.85M | 70.46M | 50.64M | 38.00M | 37.19M | 31.35M | 36.95M | 38.64M | 32.82M | 26.20M | 19.40M | 18.20M | 17.50M |
| Interest Income | 18.15M | 2.53M | 527.00K | 1.83M | 4.22M | 3.29M | 1.42M | 1.19M | 677.00K | 373.00K | 951.00K | 3.10M | 1.02M | 2.05M | 1.37M | 5.54M | 10.79M | 8.70M | 4.66M | 1.55M | 1.81M | 2.55M | 5.86M | 5.92M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 8.31M | 6.88M | 3.74M | 760.00K | 0.00 | 0.00 | 77.00K | 83.00K | 88.00K | 82.00K | 56.00K | 233.00K | 237.00K | 98.00K | 143.00K | 93.00K | 102.00K | 130.00K | 464.00K | 672.00K | 736.00K | 757.00K | 1.00M | 12.28M | 0.00 | 900.00K | 0.00 | 400.00K |
| Depreciation & Amortization | 1.03M | 868.00K | 783.00K | 935.00K | 776.00K | 59.00K | 76.00K | 81.00K | 56.00K | 47.00K | 320.00K | 830.00K | 1.58M | 1.61M | 1.75M | 2.42M | 1.93M | 1.59M | 3.74M | 3.91M | 4.12M | 4.59M | 4.37M | 4.65M | 3.70M | 1.70M | 1.60M | 1.20M |
| EBITDA | -174.78M | -134.15M | -111.59M | -73.92M | -67.77M | -26.96M | -29.18M | -30.57M | 803.00K | -35.62M | -38.06M | -67.82M | -95.04M | -109.67M | -68.29M | -59.91M | -62.84M | -47.36M | -35.85M | -32.23M | -26.06M | -31.11M | -30.65M | -21.56M | -17.10M | -10.90M | -9.30M | -11.00M |
| EBITDA Ratio | -73,747.68% | -22,654.19% | -8,010.70% | -29,611.46% | -15,761.96% | -3,051.88% | -2,613.99% | -477.99% | 3.92% | -3,117.00% | -2,823.46% | -2,434.81% | -3,388.72% | -1,160.74% | -4,078.27% | -2,320.37% | -1,001.86% | -1,623.19% | -13,736.21% | 1,226.97% | -2,153.24% | -2,492.79% | -517.65% | -326.21% | 116.67% | -200.00% | -152.05% | -241.51% |
| Operating Income | -193.94M | -138.55M | -114.00M | -76.91M | -72.51M | -31.07M | -29.26M | -30.65M | -559.00K | -36.31M | -38.96M | -71.76M | -96.12M | -111.17M | -70.23M | -67.04M | -62.84M | -47.36M | -37.71M | -81.29M | -30.18M | -35.70M | -35.02M | -26.21M | -20.80M | -12.60M | -10.90M | -12.20M |
| Operating Income Ratio | -81,832.91% | -23,246.64% | -8,183.70% | -30,400.40% | -15,761.96% | -2,914.92% | -2,746.95% | -497.34% | -1.54% | -3,149.35% | -3,036.48% | -2,648.87% | -3,942.41% | -3,120.04% | -4,069.18% | -2,391.87% | -824.44% | -1,445.22% | -13,003.45% | -7,719.37% | -2,570.70% | -2,860.58% | -967.38% | -396.61% | -385.19% | -185.29% | -149.32% | -230.19% |
| Total Other Income/Expenses | 9.82M | -3.35M | -2.11M | 1.30M | 3.96M | 4.06M | 1.34M | 1.11M | 605.00K | 642.00K | 579.00K | 2.88M | -737.00K | -210.00K | 50.00K | 5.02M | 26.14M | 16.00M | 4.18M | 880.00K | 297.00K | 0.00 | -11.91M | 0.00 | -23.40M | 2.70M | 1.80M | 1.80M |
| Income Before Tax | -184.13M | -141.90M | -116.11M | -75.62M | -68.55M | -27.02M | -27.92M | -29.54M | 46.00K | -35.67M | -38.38M | -68.88M | -96.85M | -111.38M | -70.18M | -62.02M | -36.70M | -31.37M | -33.53M | -80.41M | -29.88M | 0.00 | -46.93M | 0.00 | -44.20M | -9.90M | -9.10M | -10.40M |
| Income Before Tax Ratio | -77,690.72% | -23,808.89% | -8,335.39% | -29,888.14% | -14,901.74% | -2,534.43% | -2,621.22% | -479.34% | 0.13% | -3,093.67% | -2,991.35% | -2,542.67% | -3,972.64% | -3,125.93% | -4,066.28% | -2,212.67% | -481.46% | -957.13% | -11,561.38% | -7,635.80% | -2,545.40% | 0.00% | -1,296.38% | 0.00% | -818.52% | -145.59% | -124.66% | -196.23% |
| Income Tax Expense | 0.00 | -868.00K | 4.84M | -7.00K | -5.00M | 4.06M | 1.34M | 1.11M | 32.00K | 35.00K | 56.00K | -597.00K | 5.68M | 31.25M | -3.14M | -5.87M | -26.14M | -16.00M | -4.19M | 44.27M | -297.00K | -1.79M | 7.05M | 19.62M | 25.60M | -1.80M | -1.30M | -1.50M |
| Net Income | -184.13M | -141.03M | -120.95M | -75.61M | -63.55M | -27.02M | -27.92M | -29.54M | 46.00K | -35.67M | -38.38M | -68.88M | -96.85M | -111.38M | -70.18M | -62.02M | -36.70M | -31.37M | -33.53M | -80.41M | -29.88M | -33.91M | -42.07M | -45.83M | -46.40M | -10.80M | -9.60M | -10.70M |
| Net Income Ratio | -77,690.72% | -23,663.26% | -8,682.84% | -29,885.38% | -13,815.43% | -2,534.43% | -2,621.22% | -479.34% | 0.13% | -3,093.67% | -2,991.35% | -2,542.67% | -3,972.64% | -3,125.93% | -4,066.28% | -2,212.67% | -481.46% | -957.13% | -11,561.38% | -7,635.80% | -2,545.40% | -2,716.99% | -1,162.24% | -693.49% | -859.26% | -158.82% | -131.51% | -201.89% |
| EPS | -0.32 | -0.37 | -0.37 | -0.28 | -0.33 | -0.15 | -0.18 | -0.19 | 0.00 | -0.23 | -0.30 | -0.54 | -0.78 | -1.14 | -0.80 | -0.79 | -0.49 | -0.47 | -0.58 | -1.79 | -0.97 | -1.37 | -1.90 | -2.20 | -3.00 | -0.94 | -0.91 | -2.08 |
| EPS Diluted | -0.32 | -0.37 | -0.37 | -0.28 | -0.33 | -0.15 | -0.18 | -0.19 | 0.00 | -0.23 | -0.30 | -0.54 | -0.78 | -1.14 | -0.80 | -0.79 | -0.49 | -0.47 | -0.58 | -1.79 | -0.97 | -1.37 | -1.90 | -2.20 | -3.00 | -0.94 | -0.91 | -1.38 |
| Weighted Avg Shares Out | 570.65M | 380.78M | 327.63M | 271.46M | 190.16M | 176.50M | 159.22M | 159.05M | 158.04M | 153.54M | 127.93M | 126.94M | 124.51M | 97.60M | 88.08M | 78.19M | 74.21M | 66.06M | 57.88M | 44.88M | 30.97M | 24.66M | 22.12M | 20.87M | 15.49M | 11.44M | 10.55M | 5.15M |
| Weighted Avg Shares Out (Dil) | 570.65M | 380.78M | 327.63M | 271.46M | 190.16M | 176.50M | 159.22M | 159.05M | 162.66M | 153.54M | 128.38M | 126.94M | 124.51M | 97.60M | 88.08M | 78.19M | 74.21M | 66.06M | 57.88M | 44.88M | 30.97M | 24.66M | 22.12M | 20.87M | 15.49M | 11.44M | 10.55M | 7.74M |
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 2,910,780 shares of Geron common stock as inducements to newly hired employees in connection...
Geron (GERN) Reports Q1 Loss, Tops Revenue Estimates
Geron (GERN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.07 per share a year ago.
Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported financial results and business highlights for the first quarter 2024. “Since the FDA ODAC's 12 to...
The Top 3 Penny Stocks to Buy in April 2024
Investing in certain penny stocks to buy during a volatile economy can present unique opportunities for investors. Typically priced below $5 per share (at a discount), these stocks often exhibit heightened volatility, translating into significant short-term gains for those adept...
Geron: FDA PDUFA Review With Continued Imetelstat Advancement
Geron Corporation has a PDUFA date of June 16th of 2024 for the FDA to decide upon whether imetelstat should be approved for patients with low-risk myelodysplastic syndrome. The FDA Oncologic Drugs Advisory Committee already voted in favor of imetelstat...
3 'Buy-Rated' Biotech Stocks Under $10
Today, we look at three small-cap biotech/biopharma stocks. All three have attractive risk/reward profiles and potential catalysts on the horizon. An investment synopsis on all three firms is presented in the paragraphs below.
Geron to Announce First Quarter 2024 Financial Results on May 2, 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its first quarter 2024 financial results and business highlights before the market opens on Thursday, May 2, 2024 via press release, which...
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 243,000 shares of Geron common stock as inducements to newly hired employees in connection...
Geron to Participate at Upcoming Investor Conferences in April
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer, is scheduled to present at the following virtual investor conferences: 23rd Annual Needham Virtual Healthcare...
Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
Geron Inc. NASDAQ: GERN is a clinical-stage biotech in the medical sector focused on developing cell therapies to treat certain types of blood cancers and myeloid hematologic malignancies. Their lead drug is imetelstat, which blocks a protein called telomerase to...
Source: https://incomestatements.info
Category: Stock Reports